Assie M B, Koek W
Neurobiology Division II, Centre de Recherche Pierre Fabre, Castres, France.
Neuropharmacology. 1996 Feb;35(2):213-22. doi: 10.1016/0028-3908(95)00169-7.
The present work examined, using in vivo microdialysis, the effects of 0.16-10 mg/kg of the beta-adrenoceptor antagonists, (-)-pindolol and (+/-)-tertatolol, which have additional 5-HT1A receptor antagonist properties, on extracellular 5-HT levels in the ventral hippocampus of chloral hydrate-anaesthetized rats. These effects were compared with those observed when (-)-pindolol and (+/-)-tertatolol were given together with the 5-HT1A agonist 8-OH-DPAT (0.31 mg/kg i.p.). When given alone, (-)-pindolol and (+/-)-tertatolol increased 5-HT levels not only after systemic administration (at 2.5 and 10 mg/kg s.c.), but also when perfused locally through the dialysis probe (at a concentration of 10 microM). At doses equal to or lower than those that increased 5-HT when given alone, (-)-pindolol and (+/-)-tertatolol inhibited the decrease of extracellular 5-HT levels induced by 8-OH-DPAT. At higher doses, however, (-)-pindolol and (+/-)-tertatolol were less able to reverse these effects of 8-OD-DPAT. The selective beta 1-adrenoceptor antagonist, (+/-)-betaxolol, did not alter 5-HT levels, either when given alone or when given together with 8-OD-DPAT. Although the antagonism of the 8-OH-DPAT-induced decrease of 5-HT levels by (-)-pindolol and (+/-)-tertatolol is likely to be related to their 5-HT1A antagonist properties, their ability to increase extracellular 5-HT levels when given alone may involve interactions with 5-HT1B receptors at hippocampal 5-HT terminals.
本研究采用体内微透析技术,考察了具有5-HT1A受体拮抗特性的β-肾上腺素受体拮抗剂(-)-吲哚洛尔和(±)-替他洛尔,剂量为0.16 - 10mg/kg时,对水合氯醛麻醉大鼠腹侧海马细胞外5-羟色胺(5-HT)水平的影响。将这些影响与(-)-吲哚洛尔和(±)-替他洛尔与5-HT1A激动剂8-羟基二丙胺基四氢萘(8-OH-DPAT,0.31mg/kg腹腔注射)联合给药时的观察结果进行了比较。单独给药时,(-)-吲哚洛尔和(±)-替他洛尔不仅在全身给药后(皮下注射2.5和10mg/kg)会增加5-HT水平,而且当通过透析探针局部灌注时(浓度为10μM)也会增加5-HT水平。在等于或低于单独给药时增加5-HT水平的剂量下,(-)-吲哚洛尔和(±)-替他洛尔可抑制8-OH-DPAT诱导的细胞外5-HT水平降低。然而,在较高剂量下,(-)-吲哚洛尔和(±)-替他洛尔逆转8-OD-DPAT这些作用的能力较弱。选择性β1-肾上腺素受体拮抗剂(±)-倍他洛尔,无论是单独给药还是与8-OD-DPAT联合给药,均不会改变5-HT水平。尽管(-)-吲哚洛尔和(±)-替他洛尔对8-OH-DPAT诱导的5-HT水平降低的拮抗作用可能与其5-HT1A拮抗剂特性有关,但它们单独给药时增加细胞外5-HT水平的能力可能涉及与海马5-HT终末的5-HT1B受体相互作用。